Oraya Supplement: Oraya Therapy for Wet AMD, Real World Clinical Outcomes

Default banner image for Oraya Supplement: Oraya Therapy for Wet AMD, Real World Clinical Outcomes
Age-related macular degeneration (AMD) affects an estimated 30 million to 50 million people worldwide and is the leading cause of severe vision loss in higher income countries. Neovascular AMD accounts for about 10 per cent of AMD cases, but for about 90 per cent of the severe vision loss that AMD causes. It affects approximately 1.3 per cent of people over 50 years old, with approximately 600,000 new cases of neovascular AMD diagnosed annua Download Supplement - click here
Tags: ocular pathology